BACH2 and acute myeloid leukemia: Interestingly, infant AML harbor a BACH2-enriched B cell transcriptional signature (Fig. 7) [37], which suggests therapeutic efficacy of recently developed BACH2 inhibitors as well as a B ALL adapted therapy [37, 48].